Clinical outcomes following laparoscopic management of pT3 renal masses: A large, multi-institutional cohort

Authors

  • Jasmir G Nayak University of Manitoba, Section of Urology AND University of Washington, Department of Urology, Seattle, WA, USA http://orcid.org/0000-0002-1360-7798
  • Premal Patel University of Manitoba, Section of Urology
  • Jennifer Bjazevic University of Manitoba, Section of Urology
  • Zhihui Lui Cancer Care Ontario
  • Olli Saarela University of Toronto, Dalla Lana School of Public Health
  • Anil Kapoor McMaster University, Division of Urology
  • Ricardo Rendon Dalhousie University, Department of Urology
  • Jun Kawakami University of Calgary, Southern Alberta Institute of Urology
  • Simon Tanguay McGill University, Division of Urology
  • Rodney H Breau University of Ottawa, The Ottawa Hospital Research Institute
  • Peter C Black University of British Columbia, Department of Urologic Sciences
  • Darrel E Drachenberg University of Manitoba, Section of Urology

DOI:

https://doi.org/10.5489/cuaj.2848

Abstract

Introduction: We described the clinical and oncological outcomes of patients treated by laparoscopic surgery for non-metastatic pT3 renal cell carcinoma (RCC).

Methods: We queried a multi-institutional database for patients diagnosed with non-metastatic pathological T3 RCC from 13 Canadian centres treated laparoscopically (radical or partial nephrectomy) between 2008 and 2014. Clinical and pathological outcomes were evaluated. Progression was defined as the development of recurrence or metastatic disease. Log-rank testing and Kaplan-Meier statistical methods assessed for differences and estimated progression-free survival (PFS).

Results: In total, 176 patients were identified with a median age of 64 years. The median tumour size was 7.0 cm. Pre-clinical stage was cT1 to cT4 in 39%, 28%, 30% and 3%, respectively. The median blood loss was 150 mL (range: 0–6000) and the median operative time was 124 minutes (range: 60–360). Most lesions were clear cell RCC (80%). After a median follow-up of 17.6 months (range: 0.2–75.0), disease progression occurred in 26% (46/176) of patients, consisting of local recurrence in 7% (3/46), and metastatic disease in 93% (43/46). The 3-year PFS was 67%, with a median PFS of 49 months. Of those who progressed, the median time to progression was 10.3 months.

Conclusions: This study is the largest cohort of pT3 RCC patients treated laparoscopically in the literature and suggests that for properly selected patients, laparoscopic management of locally advanced renal masses yields acceptable short-term oncological outcomes.

Downloads

Download data is not yet available.

Downloads

Published

2015-12-14

How to Cite

Nayak, J. G., Patel, P., Bjazevic, J., Lui, Z., Saarela, O., Kapoor, A., Rendon, R., Kawakami, J., Tanguay, S., Breau, R. H., Black, P. C., & Drachenberg, D. E. (2015). Clinical outcomes following laparoscopic management of pT3 renal masses: A large, multi-institutional cohort. Canadian Urological Association Journal, 9(11-12), 397–402. https://doi.org/10.5489/cuaj.2848

Issue

Section

Original Research